演題抄録

臓器別シンポジウム

開催概要
開催回
第51回・2013年・京都
 

New therapies for advanced prostate cancer; choose to block, disrupt, modulate?

演題番号 : OS12-1

[筆頭演者]
David I. Quinn:1 
[共同演者]
Tanya B Dorff:1、Amir Goldkorn:1、Mitchell E Gross:1,2、Jacek K Pinski:1

1:Norris Comprehensive Cancer Center, Univ of Southern CA, USA、2:Center for Applied Molecular Medicine, Univ of Southern CA, USA

 

The last three years have seen a myriad of new therapies for advanced castration-resistant prostate cancer (CRPC) including immunotherapy (Sipuleucel-T: NEJM 2010), novel chemotherapy (Cabazitaxel: Lancet 2010), two hormonal agents (Abiraterone acetate, Enzalutamide: NEJM 2011, 2012) and bone calcium matrix targeted radionuclide (Radium 223: NEJM 2013). Further complicating this is the potential approval of other novel therapies (Prostvac (JCO 2010), Ipilimumab (Ann Oncol 2013), TAK700/Orterenol (ASCO 2012), ARN-509 (Cancer Res 2012). For patients and clinicians involved in making decisions on treatment in these settings, each therapy is welcome but presents a challenge of which patient it is best used in, when and in what sequence. A nominal sequencing of therapies in CRPC built upon a base of androgen deprivation and bone protection will be presented, beginning with considerations of immunotherapy, second-line hormonal therapy, chemotherapy and radionuclide treatment based on metastatic distribution, presence of pain and performance status. Finally, we will consider a new paradigm in therapy selection based on cancer characteristics such as active androgen receptor pathway biomarkers or clinical "anaplastic characteristics" (Aparicio AM et al. Clin Cancer Res 2013) that may help us personalize and sequence therapies in the future.

前へ戻る